包括前药和纳米催化药物在内的先进化疗策略显着提高了肿瘤选择性治疗诊断学的水平，但精细的前药筛选、繁琐的合成、无机成分的低降解性/生物相容性以及不令人满意的反应活性使治疗效果复杂化。在这里，我们通过电替代探索液态金属纳米液滴（LMND）的内在抗癌生物活性。通过利用机械可降解配体，水性 LMND 的最终尺寸出乎意料地控制为小至 ∼20 nm (LMND20)。我们证明，LMND20 具有出色的肿瘤渗透性和生物相容性，并激活肿瘤选择性载体到药物的转化，通过电替代同步消耗 Cu2 离子并产生 Ga3 离子。与活性氧的大量产生一起，多种抗癌途径导致乳腺癌细胞选择性凋亡和抗血管生成。与临床前/临床抗癌药物四硫代钼酸盐和Ga(NO3)3相比，LMND20给药显着提高了BCap-37异种移植小鼠模型的治疗效果和生存率，但没有明显的副作用。本文受版权保护。保留所有权利。本文受版权保护。版权所有。

Advanced chemotherapeutic strategies including prodrug and nanocatalytic medicine have significantly advanced tumor-selective theranostics, but delicate prodrug screening, tedious synthesis, low degradability/biocompatibility of inorganic components and unsatisfied reaction activity complicate treatment efficacies. Here we explore intrinsic anticancer bioactivity of liquid metal nanodroplet (LMND) through the galvanic replacement. By utilizing a mechano-degradable ligand, the resultant size of aqueous LMND is unexpectedly controlled as small as ∼20 nm (LMND20). We demonstrate that LMND20 presents excellent tumor penetration and biocompatibility and activates tumor-selective carrier-to-drug conversion, synchronously depleting Cu2+ ions and producing Ga3+ ions through the galvanic replacement. Together with abundant generation of reactive oxygen species, multiple anticancer pathways lead to selective apoptosis and anti-angiogenesis of breast cancer cells. Compared to the preclinical/clinical anticancer drugs of tetrathiomolybdate and Ga(NO3 )3 , LMND20 administration significantly improves the therapeutic efficacy and survival in a BCap-37 xenograft mouse model, yet without obvious side effects. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.